First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research ...

CellFE, a leader in microfluidics-based cell engineering, and Made Scientific, a leading cell therapy contract development and manufacturing organization (CDMO), today announced a strategic ...

Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing. Click here ...

The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor ...

Cell therapy is ... two basic categories: autologous cell therapies, which involve removing a patient’s cells, modifying them, and returning them to the body, and allogeneic cell therapies ...

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid ...

Nkure Therapeutics and Crispr Therapeutics partner to develop off-the-shelf CAR T therapy for oncology in India.

IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment.

Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current ...

Researchers will use Cellply's VivaCyte platform to conduct single-cell analyses of NK cells and evaluate their ability to treat the bone marrow cancer.

Blood centres were key early players in the autologous cell therapy space ... much of which is relevant for management of allogeneic cell donors as well. Most uphold reputations for white glove ...